RxDoctor Payments Data

William Tosches, MD

Neurology · Hopedale, MANPI 1841390952

Payments from drug & device makers

$2,332in general payments, 2019–2025

Across 127 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$346
  • Biogen$255
  • Mallinckrodt Enterprises LLC$250
  • UCB, Inc.$233
  • Teva Pharmaceuticals USA, Inc.$162
  • Eisai Inc.$146
  • plus $940 from 20 others

What the payments were for

  • Speaking & faculty fees$623%
  • Food & beverage$2,27197%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,332 in reported general payments places this provider in the 60th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$41,785
Medicare patients
129
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide14$128,743
Avonex Pen (4 Pack)Interferon Beta-1a11$105,416
Austedo XrDeutetrabenazine17$102,311
VumerityDiroximel Fumarate17$97,374
XcopriCenobamate32$41,915
Glatiramer Acetate18$40,598
OxycontinOxycodone Hcl13$31,297
KeppraLevetiracetam14$27,797
OnfiClobazam20$23,869
BanzelRufinamide13$20,177
BotoxOnabotulinumtoxina15$15,887
FycompaPerampanel11$13,210
Aimovig AutoinjectorErenumab-Aooe17$12,883
ZonegranZonisamide11$12,839
Aripiprazole13$9,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$78$128,74314 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$162$102,31117 claims
BiogenVumerity$255$97,37417 claims
SK Life Science, Inc.Xcopri$104$41,91532 claims
Eisai Inc.Banzel, Fycompa$146$33,38724 claims
Lundbeck LLCOnfi$14$23,86920 claims
AbbVieBotox$18$15,88715 claims
PfizerDilantin$35$5,23632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 761 neurology providers in Massachusetts.

Other neurology in Hopedale

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →